Clinical evaluation of commercial PCR assays for antimicrobal resistance in Mycoplasma genitalium and estimation of resistance-mediated mutation prevalence in Moscow and Moscow region

[1]  E. Plummer,et al.  Nonquinolone Options for the Treatment of Mycoplasma genitalium in the Era of Increased Resistance , 2020, Open forum infectious diseases.

[2]  Huiru Chen,et al.  Macrolide and fluoroquinolone associated mutations in Mycoplasma genitalium in a retrospective study of male and female patients seeking care at a STI Clinic in Guangzhou, China, 2016-2018 , 2020, BMC Infectious Diseases.

[3]  T. Pumarola,et al.  Mycoplasma genitalium macrolide resistance update: Rate among a 2016–2017 cohort of patients in Barcelona, Spain , 2020, Enfermedades infecciosas y microbiologia clinica (English ed.).

[4]  O. Zhukova,et al.  The prevalence and type of mutations of in dermatovenereological patients from the Moscow region for 2014‒2018 , 2020 .

[5]  T. Pumarola,et al.  Mycoplasma genitalium macrolide resistance update: Rate among a 2016-2017 cohort of patients in Barcelona, Spain. , 2020, Enfermedades infecciosas y microbiologia clinica.

[6]  S. Pereyre,et al.  Clinical Evaluation of Three Commercial PCR Assays for the Detection of Macrolide Resistance in Mycoplasma genitalium , 2019, Journal of Clinical Microbiology.

[7]  S. Garland,et al.  Moxifloxacin and Sitafloxacin Treatment Failure in Mycoplasma genitalium Infection: Association with parC Mutation G248T (S83I) and Concurrent gyrA Mutations. , 2019, The Journal of infectious diseases.

[8]  S. Garland,et al.  Moxifloxacin and Sitafloxacin Treatment Failure in Mycoplasma genitalium Infection: Association with parC Mutation G248T (S83I) and Concurrent gyrA Mutations. , 2019, The Journal of infectious diseases.

[9]  P. Horner,et al.  Launch of the BASHH guideline for the management of M. genitalium in adults , 2019, Sexually Transmitted Infections.

[10]  Wei Wang,et al.  Antibiotic resistance: a rundown of a global crisis , 2018, Infection and drug resistance.

[11]  S. Kutsuna,et al.  Mutations in ParC and GyrA of moxifloxacin-resistant and susceptible Mycoplasma genitalium strains , 2018, PloS one.

[12]  N. Low,et al.  Prevalence of Mycoplasma genitalium in different population groups: systematic review andmeta-analysis , 2017, Sexually Transmitted Infections.

[13]  S. Garland,et al.  Evaluation of the SpeeDx ResistancePlus MG Diagnostic Test for Mycoplasma genitalium on the Applied Biosystems 7500 Fast Quantitative PCR Platform , 2017, Journal of Clinical Microbiology.

[14]  G. Dinos.  The macrolide antibiotic renaissance , 2017, British journal of pharmacology.

[15]  Charlotte A Gaydos,et al.  Mycoplasma genitalium , 2017, The Journal of infectious diseases.

[16]  P. Totten,et al.  The Unique Microbiology and Molecular Pathogenesis of Mycoplasma genitalium. , 2017, The Journal of infectious diseases.

[17]  M. Unemo,et al.  Prevalence of macrolide and fluoroquinolone resistance-mediating mutations in Mycoplasma genitalium in five cities in Russia and Estonia , 2017, PloS one.

[18]  S. Garland,et al.  Prospective Evaluation of ResistancePlus MG, a New Multiplex Quantitative PCR Assay for Detection of Mycoplasma genitalium and Macrolide Resistance , 2017, Journal of Clinical Microbiology.

[19]  T. Grossman,et al.  Resistance to Macrolide Antibiotics in Public Health Pathogens. , 2016, Cold Spring Harbor perspectives in medicine.

[20]  M. Cusini,et al.  2016 European guideline on Mycoplasma genitalium infections , 2016, Journal of the European Academy of Dermatology and Venereology.

[21]  M. Cusini,et al.  European guideline on Mycoplasma genitalium infections , 2016 .

[22]  A. Rowhani-Rahbar,et al.  Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  M. Unemo,et al.  Treatment efficacy, treatment failures and selection of macrolide resistance in patients with high load of Mycoplasma genitalium during treatment of male urethritis with josamycin , 2015, BMC Infectious Diseases.

[24]  D. Taylor-Robinson,et al.  Mycoplasma genitalium: from Chrysalis to Multicolored Butterfly , 2011, Clinical Microbiology Reviews.

[25]  H. Weiss,et al.  Association of Mycoplasma genitalium and HIV infection: a systematic review and meta-analysis , 2009, AIDS.

[26]  S. Tabrizi,et al.  Azithromycin treatment failure in Mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  J. Blondeau.  Fluoroquinolones: mechanism of action, classification, and development of resistance. , 2004, Survey of ophthalmology.

[28]  T. Deguchi,et al.  Analysis of the gyrA and parC genes of Mycoplasma genitalium detected in first-pass urine of men with non-gonococcal urethritis before and after fluoroquinolone treatment. , 2001, The Journal of antimicrobial chemotherapy.

[29]  J. Tully,et al.  A NEWLY DISCOVERED MYCOPLASMA IN THE HUMAN UROGENITAL TRACT , 1981, The Lancet.